In focus · trending topic

suprachoroidal drug delivery

16 stories · following the connections

Clearside Biomedical, Inc. to Present at the Cowen and Company 37th Annual Health Care Conference

By Nasdaq OMXMar 1, 2017, 10:00 PM UTC

Clearside Biomedical, Inc. Receives Notice of Allowance for Ninth U.S. Patent

By Nasdaq OMXMar 1, 2017, 1:01 PM UTC

Clearside Biomedical, Inc. Receives Notice of Allowance for Ninth U.S. Patent

By Nasdaq OMXMar 1, 2017, 1:01 PM UTC

Clearside Biomedical, Inc. Redirects Pre-Clinical AMD Research Resources Toward Ongoing DME Clinical Development Program

By Nasdaq OMXFeb 27, 2017, 1:01 PM UTC

Clearside Biomedical, Inc. Announces First Patient Randomized in Phase 3 Clinical Trial of Zuprata™ Used Together With Eylea in Subjects With Retinal Vein Occlusion

By Nasdaq OMXFeb 16, 2017, 12:30 PM UTC

Clearside Biomedical, Inc. Receives Notice of Allowance for Seventh U.S. Patent

By Nasdaq OMXJan 5, 2017, 9:30 PM UTC

Clearside Biomedical, Inc. Appoints Richard Beckman, M.D., as Chief Medical Officer

By Nasdaq OMXJan 4, 2017, 9:30 PM UTC

Clearside Biomedical, Inc. Added to NASDAQ Biotechnology Index

By Nasdaq OMXDec 14, 2016, 9:15 PM UTC